Evaluation Review

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click Here for More Information

Click here for free access to the SAGE eReference platform!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levine, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Levine, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Evaluation Review, Vol. 14, No. 5, 447-463 (1990)
DOI: 10.1177/0193841X9001400502

Women and HIV/AIDS Research

The Barriers to Equity

Carol Levine

Citizens Commission on AIDS

Despite the prevalence of HIV disease among women, drug trials to date have enrolled mostly men. In drug trial recruitment, HIV-infected women typically suffer quadruple jeopardy: first, they may be excluded because they are either potentially or actually pregnant; second, they may be excluded because they are members of minority groups and lack access to the health care system and to research institutions; third, they may be excluded because they are drug users and are presumed to be noncompliant subjects; fourth, they may be excluded because most of the trials so far have focused on AIDS itself, and many of the women have been infected recently and have not developed a clinical diagnosis ofAIDS. Efforts to enroll women in HIV/AIDS drug trials must surmount the barriers of the regulatory system; the resk-avoidance practices of the pharmaceutical industry; the lack of access to the health care system; the suspicion of many minority communities, based on past abuses, that research presents risks but no benefits; and the needs of women for child care and transportation in order to participate. Women should not be categorically excluded from research, but there may be special, very limited circumstances in which exclusion of pregnant women may be justified.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Journal of Health Politics, Policy and LawHome page
J. R. Schroedel and P. Peretz
A Gender Analysis of Policy Formation: The Case of Fetal Abuse
Journal of Health Politics Policy and Law, June 1, 1994; 19(2): 335 - 360.
[Abstract] [PDF]


Home page
The Counseling PsychologistHome page
M. A. Hoffman
Multiculturalism as a Force in Counseling Clients with HIV-Related Concerns
The Counseling Psychologist, October 1, 1993; 21(4): 712 - 731.
[Abstract]


Home page
Criminal Justice and BehaviorHome page
D. K. MARCUS and R. BIBACE
A Developmental Analysis of Female Prisoners' Conceptions of Aids
Criminal Justice and Behavior, September 1, 1993; 20(3): 240 - 253.
[Abstract]


Home page
J Law Med EthicsHome page
C. Levine and G. L. Stein
What's in a Name? The Policy Implications of the CDC Definition of AIDS
J. Law Med. Ethics, September 1, 1991; 19(3-4): 278 - 290.
[PDF]